Disposition of the dipeptidyl peptidase 4 inhibitor sitagliptin in rats and dogs

Drug Metabolism and Disposition

Volumn 35, Issue 4, 2007, Pages 525-532

  Beconi, Maria G ^a   Reed, James R ^a   Teffera, Yohannes ^a   Xia, Yuan Qing ^a   Kochansky, Christopher J ^a   Liu, David Q ^a   Xu, Shiyao ^a   Elmore, Charles S ^a   Ciccotto, Suzanne ^a   Hora, Donald F ^a   Stearns, Ralph A ^a   Vincent, Stella H ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINE; CARBON 14; DIPEPTIDYL PEPTIDASE IV INHIBITOR; DRUG METABOLITE; PHOSPHATE; PIPERAZINE DERIVATIVE; SITAGLIPTIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; AREA UNDER THE CURVE; ARTICLE; BILIARY EXCRETION; CONTROLLED STUDY; CYCLIZATION; DOG; DRUG ABSORPTION; DRUG BILE LEVEL; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISPOSITION; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG EXCRETION; DRUG FECES LEVEL; DRUG HALF LIFE; DRUG METABOLISM; DRUG URINE LEVEL; GLOMERULUS FILTRATION RATE; GLUCURONIDATION; HUMAN; HUMAN CELL; HUMAN TISSUE; HYDROXYLATION; KIDNEY CLEARANCE; LIQUID CHROMATOGRAPHY; MALE; NONHUMAN; PLASMA CLEARANCE; PRIORITY JOURNAL; RAT; SINGLE DRUG DOSE; SULFATION; TANDEM MASS SPECTROMETRY; URINARY EXCRETION;

ADENOSINE DEAMINASE; ADMINISTRATION, ORAL; ANIMALS; ANTIGENS, CD26; BILE; BIOLOGICAL AVAILABILITY; BIOTRANSFORMATION; CYCLIZATION; DOGS; ENZYME INHIBITORS; FECES; GLUCURONIDES; GLYCOPROTEINS; HAPLORHINI; HUMANS; HYDROXYLATION; HYPOGLYCEMIC AGENTS; KIDNEY; MALE; MICROSOMES, LIVER; MOLECULAR STRUCTURE; OXIDATION-REDUCTION; PROTEIN BINDING; PYRAZINES; RATS; RATS, SPRAGUE-DAWLEY; SPECIES SPECIFICITY; SULFURIC ACID ESTERS; TRIAZOLES;

CANIS FAMILIARIS; RATTUS;

EID: 34047118068     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.106.013110     Document Type: Article

References (34)

1. Ahren B, Landin-Olsson M, Jansson PA, Svenson M, Holmes D, and Schweizer A (2004) Inhibition of dipeptidyl peptidase-4 reduces glycemia, sustains insulin levels, and reduces glucagon levels in type 2 diabetes. J Clin Endocrinol Metab 89:2078-2084.
2. Baillie TA and Davis MR (1993) Mass spectrometry in the analysis of glutathione conjugates. Biol Mass Spectrom 22:319-325.
3. Balkan B, Kwasnik L, Miserendino R, Holst JJ, and Li X (1999) Inhibition of dipeptidyl peptidase IV with NVP DPP728 increases plasma GPL-1 (7-36 amide) concentrations and improves oral glucose tolerance in obese Zucker rats. Diabetologia 42:1324-1331.
4. Beconi MG, Mao A, Liu DQ, Kochansky C, Pereira T, Raab C, Pearson P, and Lee Chiu S-H (2003) Metabolism of a dipeptidyl peptidase IV (DP-IV) inhibitor in rats, dogs, and monkeys with selective carbamoyl glucuronidation of the primary amine in dogs. Drug Metab Dispos 31:1269-1277.
5. Bergman AJ, Stevens C, Zhou YY, Yi B, Laethem M, De Smet M, Snyder K, Hilliard D, Tanaka W, Zeng W, et al. (2006) Pharmacokinetic and pharmacodynamic properties of multiple oral doses of sitagliptin, a dipeptidyl peptidase-IV inhibitor: a double-blind, randomized, placebo-controlled study in healthy male volunteers. Clin Ther 28:55-72.
6. Caron N and Kramp R (1999) Measurement of changes in glomerular filtration rate induced by atrial natriuretic peptide in the rat kidney. Exp Physiol 84:689-696.
7. Cornell S (2006) Vildagliptin (LAF237): a dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes mellitus. J Pharm Technol 22:105-109.
8. Delbressine LPC, Funke CW, van Tilborg M, and Kaspersen FM (1990) On the formation of carbamate glucuronides. Xenobiotica 20:133-134.
9. Drucker DJ (2006) The biology of incretin hormones. Cell Metab 3:153-165.
10. Gautier JF, Fetita S, Sobngwi E, and Salaun-Martin C (2005) Biological actions of the incretins GIP and GLP-1 and therapeutic perspectives in patients with type 2 diabetes. Diabetes Metab 31:233-242.
11. Gorrell MD (2005) Dipeptidyl peptidase IV and related enzymes in cell biology and liver disorders. Clin Sci (Lond) 108:277-292.
12. Green BD, Flatt PR, and Bailey CJ (2006) Inhibition of dipeptidyl peptidase IV activity as a therapy of type 2 diabetes. Expert Opin Emerg Drugs 11:525-539.
13. Greenaway W and Whatley FR (1987) Formation of N-carboxy compounds during trimethylsilanization of amino acids in the presence of carbon dioxide. J Chromatogr 409:383-389.
14. Haller M, Muller W, Binder H, Estelberger W, and Arnold P (1998) Single injection inulin clearance - a simple method for measuring glomerular filtration rate in dogs. Res Vet Sci 64:151-156.
15. Herman G, Hanefeld M, Wu M, Chen X, Zhao P, and Stein P (2005a) Effect of MK-0431, a dipeptidyl peptidase IV (DPP-IV) inhibitor, on glycemic control after 12 weeks in patients with type 2 diabetes. Diabetes 54 (Suppl 1):A134.
16. Herman GA, Stevens C, Van Dyck K, Bergman A, Yi B, De Smet M, Snyder K, Hilliard D, Tanen M, Tanaka W, et al. (2005b) Pharmacokinetics and pharmacodynamics of single doses of sitagliptin, an inhibitor of dipeptidyl peptidase-IV, in healthy subjects. Clin Pharmacol Ther 78:675-688.
17. Herman GA, Zhao PL, Dietrich B, Golor G, Schrodter A, Keymeulen B, Lasseter KC, Kipnes MS, Hilliard D, Tanen M, et al. (2004) The DP-IV inhibitor MK-0431 enhances active GLP-1 and reduces glucose following an OGTT in type 2 diabetics. Diabetes 53 (Suppl 2):A82.
18. Kim D, Wang L, Beconi M, Eiermann GJ, Fisher MH, He H, Hickey G-J, Kowalchick JE, Leiting B, Lyons K, et al. (2005) (2R)-4-oxo-4-[3- (trifluoromethyl)-5,6-dihydro[1,2,4]triazolo[4,3-a] pyrazin-7(8H)-yl]-1-(2,4,5- trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J Med Chem 48:141-151.
19. Krieter PA, Colletti AE, Doss GA, and Miller RR (1994) Disposition and metabolism of the hypoglycemic agent pioglitazone in rats. Drug Metab Dispos 22:625-630.
20. Liu DQ, Arison BH, Stearns RA, Kim D, and Vincent SH (2007) Characterization of two cyclic metabolites of sitagliptin. Drug Metab Dispos 35:000-000.
21. Liu DQ and Pereira T (2002) Interference of a carbamoyl glucuronide metabolite in quantitative mass spectrometry. Rapid Commun Mass Spectrom 16:142-146.
22. Mentlein R, Gallwitz B, and Schmidt WE (1993) Dipeptidyl peptidase IV hydrolyzes gastric inhibitory polypeptide, glucagon-like peptide-1 (7-36) amide, peptide histidine methionine and is responsible for their degradation in human serum. Eur J Biochem 214:829-835.
23. 2 adducts of certain amino acids, peptides, and sperm whale myoglobin studied by carbon 13 and proton nuclear magnetic resonance. J Biol Chem 249:7484-7494.
24. Mu J, Woods J, Zhou YP, Roy RS, Li Z, Zycband E, Feng Y, Zhu L, Li C, Howard AD, et al. (2006) Chronic inhibition of dipeptidyl peptidase-4 with a sitagliptin analog preserves pancreatic β-cell mass and function in a rodent model of type 2 diabetes. Diabetes 55:1695-1704.
25. Park B, Kitteringham N, and O'Neill P (2001) Metabolism of fluorine-containing drugs. Annu Rev Pharmacol Toxicol 41:443-470.
26. Pospisilik JA, Stafford SG, Demuth H-U, Brownsey R, Parkhouse W, Finegood DT, McIntosh CHS, and Pederson RA (2002) Long-term treatment with the dipeptidyl peptidase IV inhibitor P32/98 causes sustained improvements in glucose tolerance, insulin sensitivity, hyperinsulinemia, and β-cell glucose responsiveness in VDF (fa/fa) Zucker rats. Diabetes 51:943-950.
27. Raucy JL and Lasker JM (1991) Isolation of P450 enzymes from human liver. Methods Enzymol 206:557-587.
28. Rietjens IM, den Besten C, Hanzlik RP, and van Bladeren PJ (1997) Cytochrome P450-catalyzed oxidation of halobenzene derivatives. Chem Res Toxicol 10:629-635.
29. Schaefer WH (1992) Formation of a carbamoyl glucuronide conjugate of carvedilol in vitro using dog and rat liver microsomes. Drug Metab Dispos 20:130-133.
30. Scott R, Herman G, Zhao P, Chen X, Wu M, and Stein P (2005) Twelve-week efficacy and tolerability of MK-0431, a dipeptidyl peptidase IV (DPP-IV) inhibitor, in the treatment of type 2 diabetes (T2D). Diabetes 54 (Suppl 1):A10.
31. Sugahara K and Kitagawa H (2002) Heparin and heparan sulfate biosynthesis. IUBMB-Life 54:163-175.
32. 14C]sitagliptin in humans. Drug Metab Dispos 35:000-000.
33. Xia YQ, Hop CE, Liu DQ, Vincent SH, and Chiu SH (2001) Parallel extraction columns and parallel analytical columns coupled with liquid chromatography/tandem mass spectrometry for on-line simultaneous quantification of a drug candidate and its six metabolites in dog plasma. Rapid Commun Mass Spectrom 15:2135-2144.
34. Zander M, Madsbad S, Lysgaard J, and Holst JJ (2002) Effect of 6-week course of glucagon-like peptide 1 on glycaemic control, insulin sensitivity, and β-cell function in type 2 diabetes: a parallel-group study. Lancet 359:824-830.